Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox!

Literature Review, August 2018


Hexokinase 2 is dispensable for T cell-dependent immunity. Mehta MM1, Weinberg SE1, Steinert EM1, et al. Cancer Metab. 2018 Aug 17;6:10. doi: 10.1186/s40170-018-0184-5. eCollection 2018.

Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. Rizzolio S1,2, Cagnoni G1,2, Battistini C1,2, et al. J Clin Invest. 2018 Aug 31;128(9):3976-3990. doi: 10.1172/JCI99257. Epub 2018 Aug 13.


A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting. Sorber L1,2, Zwaenepoel K3,4, De Winne K5, et al. Cancers (Basel). 2018 Aug 27;10(9). pii: E290. doi: 10.3390/cancers10090290.

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. Raad S1, Hanna N1, Jalal S1, Bendaly E1, Zhang C1, Nuguru S1, Oueini H1, Diab K1. South Med J. 2018 Aug;111(8):484-488. doi: 10.14423/SMJ.0000000000000846.

Attitudes towards lung cancer screening in a population sample. Smits SE1, McCutchan GM1, Hanson JA2, Brain KE1. Health Expect. 2018 Aug 7. doi: 10.1111/hex.12819. [Epub ahead of print]


Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Presley CJ1, Tang D2, Soulos PR3, et al. JAMA. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824.

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. Lee DH1, Tsao MS2, Kambartel KO3, et al. PLoS One. 2018 Aug 27;13(8):e0202865. doi: 10.1371/journal.pone.0202865. eCollection 2018.

Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort. Kaminetzky M1, Milch HS2, Shmukler A1, et al. J Am Coll Radiol. 2018 Aug 23. pii: S1546-1440(18)30858-5. doi: 10.1016/j.jacr.2018.07.011. [Epub ahead of print]

Yield of Low-Dose Computerized Tomography Screening for Lung Cancer in High-Risk Workers: The Case of 7189 US Nuclear Weapons Workers. Markowitz SB1, Manowitz A1, Miller JA1, Frederick JS1, Onyekelu-Eze AC1, Widman SA1, Pepper LD1, Miller A1. Am J Public Health. 2018 Aug 23:e1-e7. doi: 10.2105/AJPH.2018.304518. [Epub ahead of print]

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer. Becker DJ1, Levy BP2, Gold HT1, Sherman SE1, Makarov DV1, Schreiber D3, Wisnivesky JP2, Pass HI1. Am J Clin Oncol. 2018 Aug;41(8):820-825. doi: 10.1097/COC.0000000000000379.

Evaluating Shared Decision Making for Lung Cancer Screening. Brenner AT1,2, Malo TL2, Margolis M3, et al. JAMA Intern Med. 2018 Aug 13. doi: 10.1001/jamainternmed.2018.3054. [Epub ahead of print]


The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients. Kaida H1, Azuma K2, Kawahara A3, et al. Oncotarget. 2018 Aug 10;9(62):31971-31984. doi: 10.18632/oncotarget.25865. eCollection 2018 Aug 10.

Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer. Stokes SM1, Wakeam E2, Swords DS3, Stringham JR4, Varghese TK Jr4. Surgery. 2018 Aug 28. pii: S0039-6060(18)30471-9. doi: 10.1016/j.surg.2018.07.020. [Epub ahead of print]

Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer. Wang Y1,2, Liu B1,2, Cao P3, et al. Thorac Cancer. 2018 Aug 28. doi: 10.1111/1759-7714.12842. [Epub ahead of print]

Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences between Men and Women. Nelson DB1, Lapid DJ1, Mitchell KG1, et al. Ann Thorac Surg. 2018 Aug 14. pii: S0003-4975(18)31140-8. doi: 10.1016/j.athoracsur.2018.06.070. [Epub ahead of print]

Needlescopic-assisted thoracoscopic pulmonary anatomical lobectomy and segmentectomy for lung cancer: a bridge between multiportal and uniportal thoracoscopic surgery. Ko HJ1, Chiang XH2, Yang SM3,4, Yang MC1. Surg Today. 2018 Aug 27. doi: 10.1007/s00595-018-1707-y. [Epub ahead of print]


Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.  Gridelli C1, de Castro Carpeno J2, Dingemans AC3, et al. JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486. [Epub ahead of print}

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. Wu YL1, Lu S2, Lu Y3, et al. J Thorac Oncol. 2018 Aug 14. pii: S1556-0864(18)30721-4. doi: 10.1016/j.jtho.2018.06.012. [Epub ahead of print]

Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Barbie DA1, Spira A2, Kelly K3, Humeniuk R4, Kawashima J4, Kong S4, Koczywas M5. Clin Lung Cancer. 2018 Aug 4. pii: S1525-7304(18)30171-2. doi: 10.1016/j.cllc.2018.07.004. [Epub ahead of print]

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. Wu YL1, Zhang L1, Kim DW1, et al. J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326. [Epub ahead of print]

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Yue D1, Xu S2, Wang Q3, et al. Lancet Respir Med. 2018 Aug 24. pii: S2213-2600(18)30277-7. doi: 10.1016/S2213-2600(18)30277-7. [Epub ahead of print]

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. Xiong L1, Li R1, Sun J1, et al. Oncologist. 2018 Aug 29. pii: theoncologist.2018-0120. doi: 10.1634/theoncologist.2018-0120. [Epub ahead of print]

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Schmid S1,2, Diem S3,4,5, Li Q6, et al. Cancer Immunol Immunother. 2018 Aug 31. doi: 10.1007/s00262-018-2239-4. [Epub ahead of print]

Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses. Urushiyama H1, Jo T1,2, Yasunaga H3, et al. Cancer Med. 2018 Aug 27. doi: 10.1002/cam4.1725. [Epub ahead of print]

Association of Target Volume Margins with Locoregional Control and Acute Toxicities for Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiation Therapy. Yegya-Raman N1, Reyhan M1, Kim S2, Deek MP1, Yue N1, Zou W3, Malhotra J4, Aisner J4, Jabbour SK5. Pract Radiat Oncol. 2018 Aug 22. pii: S1879-8500(18)30253-4. doi: 10.1016/j.prro.2018.08.007. [Epub ahead of print]

24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Borghaei H1, Langer CJ2, Gadgeel S3, et al. J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942-0. doi: 10.1016/j.jtho.2018.08.004. [Epub ahead of print]

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. Oxnard GR1,2, Hu Y1, Mileham KF3, et al. AMA Oncol. 2018 Aug 2. doi: 10.1001/jamaoncol.2018.2969. [Epub ahead of print]

Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. Imai H1, Yamada Y2, Sugiyama T3, et al. Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14.


Subgroup Survival Analysis In Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT. Stam B1, Kwint M1, Guckenberger M2, et al. Int J Radiat Oncol Biol Phys. 2018 Aug 31. pii: S0360-3016(18)33682-4. doi: 10.1016/j.ijrobp.2018.08.040. [Epub ahead of print]

Initial Results of a Multicenter Phase II Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer. Sutera P1, Clump DA1, Kalash R1, D’Ambrosio D2, Mihai A3, Wang H4, Petro DP5, Burton SA1, Heron DE6. Int J Radiat Oncol Biol Phys. 2018 Aug 24. pii: S0360-10.1016/j.ijrobp.2018.08.027. [Epub ahead of print]

Inverse-Planned Deliverable 4D-IMRT for Lung SBRT. Hamzeei M1, Modiri A1, Kazemzadeh N1, Hagan A1, Sawant A1. Med Phys. 2018 Aug 28. doi: 10.1002/mp.13157. [Epub ahead of print]

Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. Palussière J1, Chomy F2, Savina M3, et al. J Cardiothorac Surg. 2018 Aug 24;13(1):91. doi: 10.1186/s13019-018-0773-y.

Targeted Sequencing and Intracranial Outcomes of Patients With Lung Adenocarcinoma Brain Metastases Treated With Radiotherapy. Press RH1, Zhang C2, Cassidy RJ1, et al. Cancer. 2018 Aug 18. doi: 10.1002/cncr.31589. [Epub ahead of print]

Knowledge-based planning for identifying high-risk stereotactic ablative radiotherapy treatment plans for lung tumors larger than 5cm. Hof SVT1, Delaney AR1, Tekatli H1, Twisk J2, Slotman BJ1, Senan S1, Dahele M1, Verbakel WF3. Int J Radiat Oncol Biol Phys. 2018 Aug 13. pii: S0360-3016(18)33543-0. doi: 10.1016/j.ijrobp.2018.08.013. [Epub ahead of print]


The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Ge W1, Xu H2, Yan Y1, Cao D3. Radiat Oncol. 2018 Aug 23;13(1):155. doi: 10.1186/s13014-018-1101-3.

Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. Nakamura M1, Onozawa M1, Motegi A1, et al. J Radiat Res. 2018 Aug 9. doi: 10.1093/jrr/rry066. [Epub ahead of print]

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. Pezzi TA1, Schwartz DL1,2, Mohamed ASR1,3, et al. JAMA Oncol. 2018 Aug 1;4(8):e174504. doi: 10.1001/jamaoncol.2017.4504. Epub 2018 Aug 9.

Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy. Ju S1, Lee HR1, Kim JY2, et al. Thorac Cancer. 2018 Aug 14. doi: 10.1111/1759-7714.12832. [Epub ahead of print]

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. Pezzi TA1, Schwartz DL1,2, Mohamed ASR1,3, et al. JAMA Oncol. 2018 Aug 1;4(8):e174504. doi: 10.1001/jamaoncol.2017.4504. Epub 2018 Aug 9.

Impact of Baseline Characteristics on Extensive-stage SCLC Patients Treated with Etoposide/ Carboplatin; a Secondary Analysis of a Phase III Study. Abdel-Rahman O1,2. Clin Respir J. 2018 Aug 3. doi: 10.1111/crj.12950. [Epub ahead of print]

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. Thomas M1, Ponce-Aix S2, Navarro A3, et al. Ann Oncol. 2018 Aug 20. doi: 10.1093/annonc/mdy326. [Epub ahead of print]

Application of prophylactic cranial irradiation in limited-stage small-cell lung cancer: which patients could benefit? Kou P1, Wang H2, Yang D1, Zhang Y3, Yu J1. Future Oncol. 2018 Aug 9. doi: 10.2217/fon-2018-0481. [Epub ahead of print]

Pilot Study: Regional Changes in Brain 18F-FDG Uptake After Prophylactic Cranial Irradiation and Chemotherapy in small cell lung cancer May Reflect Functional Changes. Eshghi N1, Garland L1, Choudhary G2, Hsu CC1, Eshghi A3, Han J1, Hamilton RJ1, Krupinski E4, Kuo PH1. J Nucl Med Technol. 2018 Aug 3. pii: jnmt.118.212316. doi: 10.2967/jnmt.118.212316. [Epub ahead of print]


Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Rahouma M1, Kamel M1, Abouarab A1, et al. Ecancermedicalscience. 2018 Aug 16;12:859. doi: 10.3332/ecancer.2018.859. eCollection 2018.

The Perceived Facilitators and Challenges of Translating a Lung Cancer Palliative Care Intervention Into Community-Based Settings. Siler S1, Mamier I, Winslow B. J Hosp Palliat Nurs. 2018 Aug;20(4):407-415. doi: 10.1097/NJH.0000000000000470.

Outcomes of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer Undergoing Chemotherapy. Dose AM1, McCabe PJ, Krecke CA, Sloan JA. J Hosp Palliat Nurs. 2018 Aug;20(4):400-406. doi: 10.1097/NJH.0000000000000461.

Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. Nguyen HQ1, Ruel N2, Macias M3, Borneman T2, Alian M4, Becher M5, Lee K6, Ferrell B7. J Pain Symptom Manage. 2018 Aug 2. pii: S0885-3924(18)30392-0. doi: 10.1016/j.jpainsymman.2018.07.018. [Epub ahead of print]

Characteristics associated with physical function trajectories in older adults with cancer during chemotherapy. Wong ML1, Paul SM2, Mastick J2, Ritchie C3, Steinman MA3, Walter LC3, Miaskowski C2. J Pain Symptom Manage. 2018 Aug 22. pii: S0885-3924(18)30436-6. doi: 10.1016/j.jpainsymman.2018.08.006. [Epub ahead of print]

Effects of shared decision making on distress and healthcare utilization among patients with lung cancer: a systematic review. Geerse OP1, Stegmann ME2, Kerstjens HAM2, et al. Pain Symptom Manage. 2018 Aug 23. pii: S0885-3924(18)30441-X. doi: 10.1016/j.jpainsymman.2018.08.011. [Epub ahead of print]

Factors Associated with Family Caregivers’ Confidence in Future Surrogate Decision Making for Persons with Cancer. Dionne-Odom JN1,2, Ejem D1, Azuero A1, et al. J Palliat Med. 2018 Aug 21. doi: 10.1089/jpm.2018.0148. [Epub ahead of print]

Depression and healthcare utilization at end of life among older adults with advanced non-small cell lung cancer. McDermott C1, Bansal A2, Ramsey SD2, Lyman GH2, Sullivan SD2. J Pain Symptom Manage. 2018 Aug 16. pii: S0885-3924(18)30401-9. doi: 10.1016/j.jpainsymman.2018.08.004. [Epub ahead of print]


6-Gingerol as an arginase inhibitor prevents urethane-induced lung carcinogenesis by reprogramming tumor supporting M2 macrophages to M1 phenotype. Yao J1, Du Z1, Li Z1, et al. Food Funct. 2018 Aug 28. doi: 10.1039/c8fo01147h. [Epub ahead of print]

Therapeutic efficacy and safety of Kang-ai injection combined with platinum-based doublet chemotherapy in advanced NSCLC: A meta-analysis. Lu Q1, Li CL2. Life Sci. 2018 Aug 23. pii: S0024-3205(18)30516-2. doi: 10.1016/j.lfs.2018.08.055. [Epub ahead of print]


Racial and Ethnic Differences in the Relationship Between Aspirin Use and Non-Small Cell Lung Cancer Risk and Survival. Erickson P1, Gardner LD2, Loffredo CA3, et al. Cancer Epidemiol Biomarkers Prev. 2018 Aug 31. pii: cebp.0366.2018. doi: 10.1158/1055-9965.EPI-18-0366. [Epub ahead of print]

Exposure to a firefighting overhaul environment without respiratory protection increases immune dysregulation and lung disease risk. Gainey SJ1, Horn GP2, Towers AE3, et al. PLoS One. 2018 Aug 21;13(8):e0201830. doi: 10.1371/journal.pone.0201830. eCollection 2018.

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? Al-Baimani K1, Jonker H1, Zhang T2, et al. Curr Oncol. 2018 Aug;25(4):e291-e297. doi: 10.3747/co.25.3978. Epub 2018 Aug 14.